Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia

Type 2 diabetes mellitus (T2DM) is a chronic disease with high-cost treatment. This study aimed to analyze the cost-effectiveness of T2DM treatment in hospitalized patients with complications of kidney and peripheral vascular disease (PVD) in Indonesia by focusing on patients of Health Social Securi...

Descripción completa

Detalles Bibliográficos
Autores principales: Priyadi, Akhmad, Permana, Hikmat, Muhtadi, Ahmad, Sumiwi, Sri A., Sinuraya, Rano K., Suwantika, Auliya A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920312/
https://www.ncbi.nlm.nih.gov/pubmed/33669379
http://dx.doi.org/10.3390/healthcare9020211
_version_ 1783658252134776832
author Priyadi, Akhmad
Permana, Hikmat
Muhtadi, Ahmad
Sumiwi, Sri A.
Sinuraya, Rano K.
Suwantika, Auliya A.
author_facet Priyadi, Akhmad
Permana, Hikmat
Muhtadi, Ahmad
Sumiwi, Sri A.
Sinuraya, Rano K.
Suwantika, Auliya A.
author_sort Priyadi, Akhmad
collection PubMed
description Type 2 diabetes mellitus (T2DM) is a chronic disease with high-cost treatment. This study aimed to analyze the cost-effectiveness of T2DM treatment in hospitalized patients with complications of kidney and peripheral vascular disease (PVD) in Indonesia by focusing on patients of Health Social Security Agency (BPJS Kesehatan). An observational study was applied by collecting data retrospectively from patients’ medical record at the biggest public hospital in West Java Province, Indonesia. Two perspectives of payer and healthcare provider were applied to estimate the treatment cost. We considered following inclusion criteria: (i) Hospitalized T2DM patients without complication, with complications of kidney and PVD during 2014–2017; (ii) member of BPJS Kesehatan; (iii) >18 years old patients; and (iv) patients with complete medical record data. The results showed that the majority patients were female (56.72%), 45–64 years old (69.40%), and had a length of stay at 4–10 days (54.48%). The greatest contributions in the total treatment cost were found to be hospital room, medical services and medicines for the treatment of T2DM without complications, with complications of kidney and PVD, respectively. From the perspective of payer, the incremental cost-effectiveness ratios (ICERs) of T2DM treatment with complications of kidney and PVD would be IDR 215,723 and IDR 234,591 per 1 mg/dL blood glucose reduction, respectively. From the perspective of healthcare provider, the ICERs of T2DM treatment with complications of kidney and PVD would be IDR 166,289 and IDR 681,853 per 1 mg/dL blood glucose reduction in both perspectives (1 US$ = IDR 13,451). In a comparison with T2DM without complication, reducing 1 mg/dL blood glucose in T2DM treatment with complication of PVD would require higher cost than in T2DM treatment with complication of kidney from both perspectives.
format Online
Article
Text
id pubmed-7920312
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79203122021-03-02 Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia Priyadi, Akhmad Permana, Hikmat Muhtadi, Ahmad Sumiwi, Sri A. Sinuraya, Rano K. Suwantika, Auliya A. Healthcare (Basel) Article Type 2 diabetes mellitus (T2DM) is a chronic disease with high-cost treatment. This study aimed to analyze the cost-effectiveness of T2DM treatment in hospitalized patients with complications of kidney and peripheral vascular disease (PVD) in Indonesia by focusing on patients of Health Social Security Agency (BPJS Kesehatan). An observational study was applied by collecting data retrospectively from patients’ medical record at the biggest public hospital in West Java Province, Indonesia. Two perspectives of payer and healthcare provider were applied to estimate the treatment cost. We considered following inclusion criteria: (i) Hospitalized T2DM patients without complication, with complications of kidney and PVD during 2014–2017; (ii) member of BPJS Kesehatan; (iii) >18 years old patients; and (iv) patients with complete medical record data. The results showed that the majority patients were female (56.72%), 45–64 years old (69.40%), and had a length of stay at 4–10 days (54.48%). The greatest contributions in the total treatment cost were found to be hospital room, medical services and medicines for the treatment of T2DM without complications, with complications of kidney and PVD, respectively. From the perspective of payer, the incremental cost-effectiveness ratios (ICERs) of T2DM treatment with complications of kidney and PVD would be IDR 215,723 and IDR 234,591 per 1 mg/dL blood glucose reduction, respectively. From the perspective of healthcare provider, the ICERs of T2DM treatment with complications of kidney and PVD would be IDR 166,289 and IDR 681,853 per 1 mg/dL blood glucose reduction in both perspectives (1 US$ = IDR 13,451). In a comparison with T2DM without complication, reducing 1 mg/dL blood glucose in T2DM treatment with complication of PVD would require higher cost than in T2DM treatment with complication of kidney from both perspectives. MDPI 2021-02-16 /pmc/articles/PMC7920312/ /pubmed/33669379 http://dx.doi.org/10.3390/healthcare9020211 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Priyadi, Akhmad
Permana, Hikmat
Muhtadi, Ahmad
Sumiwi, Sri A.
Sinuraya, Rano K.
Suwantika, Auliya A.
Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title_full Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title_fullStr Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title_full_unstemmed Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title_short Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title_sort cost-effectiveness analysis of type 2 diabetes mellitus (t2dm) treatment in patients with complications of kidney and peripheral vascular diseases in indonesia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920312/
https://www.ncbi.nlm.nih.gov/pubmed/33669379
http://dx.doi.org/10.3390/healthcare9020211
work_keys_str_mv AT priyadiakhmad costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia
AT permanahikmat costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia
AT muhtadiahmad costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia
AT sumiwisria costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia
AT sinurayaranok costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia
AT suwantikaauliyaa costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia